176 related articles for article (PubMed ID: 19092720)
1. New potential adjuncts to treatment of children with type 1 diabetes mellitus.
Raman VS; Heptulla RA
Pediatr Res; 2009 Apr; 65(4):370-4. PubMed ID: 19092720
[TBL] [Abstract][Full Text] [Related]
2. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
Albèr A; Brønden A; Knop FK
Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
[TBL] [Abstract][Full Text] [Related]
3. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
Hoogwerf BJ
Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
[TBL] [Abstract][Full Text] [Related]
4. Therapies for diabetes: pramlintide and exenatide.
Jones MC
Am Fam Physician; 2007 Jun; 75(12):1831-5. PubMed ID: 17619527
[TBL] [Abstract][Full Text] [Related]
5. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
6. Adjunct therapy for type 1 diabetes mellitus.
Lebovitz HE
Nat Rev Endocrinol; 2010 Jun; 6(6):326-34. PubMed ID: 20404854
[TBL] [Abstract][Full Text] [Related]
7. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
Ghazi T; Rink L; Sherr JL; Herold KC
Diabetes Care; 2014; 37(1):210-6. PubMed ID: 23939544
[TBL] [Abstract][Full Text] [Related]
8. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
Asmar M; Bache M; Knop FK; Madsbad S; Holst JJ
J Clin Endocrinol Metab; 2010 May; 95(5):2367-75. PubMed ID: 20194711
[TBL] [Abstract][Full Text] [Related]
9. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
[TBL] [Abstract][Full Text] [Related]
10. Pramlintide: A new tool in diabetes management.
Want LL; Ratner RE
Curr Diab Rep; 2006 Nov; 6(5):344-9. PubMed ID: 17076994
[TBL] [Abstract][Full Text] [Related]
11. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
13. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
15. The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
Jiang LL; Wang SQ; Ding B; Zhu J; Jing T; Ye L; Lee KO; Wu JD; Ma JH
J Endocrinol Invest; 2018 May; 41(5):539-547. PubMed ID: 29032494
[TBL] [Abstract][Full Text] [Related]
16. Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.
Jeha GS; Heptulla RA
Pediatr Diabetes; 2006 Apr; 7(2):122-38. PubMed ID: 16629719
[TBL] [Abstract][Full Text] [Related]
17. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
[TBL] [Abstract][Full Text] [Related]
18. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
Weyer C; Maggs DG; Young AA; Kolterman OG
Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
[TBL] [Abstract][Full Text] [Related]
19. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Reuter H; Erdmann E
Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
[TBL] [Abstract][Full Text] [Related]
20. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
Edelman SV; Weyer C
Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
